|
|
Line 84: |
Line 84: |
|
| |
|
| ==Special Considerations== | | ==Special Considerations== |
| | Shown below is a table summarizing the appropriate choice of anticoagulation therapy in special situations.<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270 }} </ref> |
| | |
| {| class="wikitable" | | {| class="wikitable" |
| |- | | |- |
| | '''Special situations''' || '''Acute HIT or subacute HIT (normal platelets and positive antibodies)''' || '''Past medical history of HIT''' | | | '''Special situations''' || '''Acute HIT or subacute HIT (normal platelets and positive antibodies)''' || '''Past medical history of HIT''' |
| |- | | |- |
| | '''[[Cardiac surgery]]''' || <u>Urgent cardiac surgery</u>: Use bivalirudin<br> <u>Non urgent cardiac surgery</u>: Delay the surgery until HIT has resolved and antibodies are negative|| <u>Negative antibodies</u>: Use heparin (short term) <br> <u>Positive antibodies</u>: Use bivalirudin | | | '''[[Cardiac surgery]]''' || <u>Urgent cardiac surgery</u>: Use [[bivalirudin]]<br> <u>Non urgent cardiac surgery</u>: Delay the surgery until HIT has resolved and antibodies are negative|| <u>Negative antibodies</u>: Use [[heparin]] (short term) <br> <u>Positive antibodies</u>: Use [[bivalirudin]] |
| |- | | |- |
| | '''[[PCI]]'''|| Use bivalirudin or argatraban ||Use bivalirudin or argatraban | | | '''[[PCI]]'''|| Use [[bivalirudin]] or [[argatraban]] ||Use [[bivalirudin]] or [[argatraban]] |
| |- | | |- |
| | '''[[Dialysis|Renal replacement therapy]]'''||Use argatroban or danaproid || Use regional citrate | | | '''[[Dialysis|Renal replacement therapy]]'''||Use [[argatroban]] or [[danaproid]] || Use regional citrate |
| |- | | |- |
| | '''[[Pregnancy]]''' ||Use danaproid|| N/A | | | '''[[Pregnancy]]''' ||Use [[danaproid]]|| - |
| |- | | |- |
| |} | | |} |
|
| |
| ==Management==
| |
| Shown below is an algorithm summarizing the approach to [[heparin induced thrombocytopenia]]. <ref name="pmid16928996">{{cite journal| author=Arepally GM, Ortel TL| title=Clinical practice. Heparin-induced thrombocytopenia. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 8 | pages= 809-17 | pmid=16928996 | doi=10.1056/NEJMcp052967 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16928996 }} </ref> <ref name="pmid22246036">{{cite journal| author=Cuker A, Cines DB| title=How I treat heparin-induced thrombocytopenia. | journal=Blood | year= 2012 | volume= 119 | issue= 10 | pages= 2209-18 | pmid=22246036 | doi=10.1182/blood-2011-11-376293 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22246036 }} </ref> <ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270 }} </ref>
| |
| <br>
| |
| {{familytree/start |summary=Heparin Induced Thrombocytopenia Managment Algorithm. }}
| |
| {{familytree | | | | | | | | | | | | K01 | | | | | | | | | | | | | | | | | | | | | | | | | | |K01='''Thrombocytopenia:'''<br><div style="float: left; text-align: left; line-height: 150% "> ❑ Platelet count <150,000/mm<sup>3</sup> or <br> ❑ >50% decrease from highest level before initiation of heparin therapy <br> ❑ Making sure patient has received heparin or [[LMWH]] in the previous 5- 14 days <br> ❑ And after ruling out other causes of [[thrombocytopenia]] <br> </div>}} }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
| |
|
| |
| {{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | |A01='''High or intermediate clinical suspicion of HIT'''<br><div style="float: left; text-align: left; line-height: 150% "> ❑ Venous/arterial thrombosis<br>❑ Unusual manifestations:
| |
| *Skin necrosis at SC heparin injection sites
| |
| *Transient global amnesia<br>
| |
| ❑ Abscence of petechiae and/or significant bleeding<br> </div>}}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | B01 | | | | | |B01='''Discontinue [[heparin]]''' }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | |,| A01 |-| A02 | |A01=[[Lepirudin]]:
| |
| ❑Bolus:0.2 mg/kg (only for life- or limb- threatening thrombosis)
| |
| ❑Continuous infusion:
| |
| *Cr < 1.0 mg/dl → 0.10 mg/kg/h
| |
| *Cr 1.0-1.6 mg/dl → 0.05 mg/kg/h
| |
| *Cr 1.6-4.5 mg/dl → 0.01 mg/kg/h
| |
| *Cr > 4.5 mg/dl → 0.005 mg/kg/h|A02=Measure [[aPTT]] 2 hrs after therapy and after each dose adjustment. Optimal aPTT<65 sec. Check baseline before starting [[warfarin]]. }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | |!| | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | |!| | |,|-| B01 |-|+| B02 |-| B03 | |B01=[[Direct thrombin inhibitors]] |B02=[[Argatroban]]:
| |
| ❑Bolus:None
| |
| ❑Continuous infusion:
| |
| *Normal organ function → 2 mcg/kg/min
| |
| *Liver dysfunction (total serum bilirubin >1.5 mg/dl), heart failure, post-cardiac surgery, anasarca → 0.5-1.2 mcg/kg/min|B03=Measure [[aPTT]] 2 hrs after therapy and after each dose adjustment. Switching to [[warfarin]] complicated due to prolonged [[PT]]. }}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | |!| | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | |`| C01 |-| C02 | |C01=[[Bivalirudin]]:
| |
| ❑Bolus: None
| |
| ❑Continuous infusion:
| |
| *Normal organ function → 0.15 mg/kg/h
| |
| *Renal or hepatic dysfunction → dose reduction may be appropriate|C02=Measure ACT 5 min after completing IV bolus }}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | C01 |-|(| | | | | | | | | | | |C01='''Initiate alternative anticoagulant therapy for at least 2-3 months''' }}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | |,| A01 |-| A02 | |A01=[[Danaparoid]]|A02=Monitoring not needed. If needed maintain anti-factor Xa 0.5-0.8 U/mL | | | | | | | | | | | | | | | |}}
| |
| {{familytree | | | | | | | | | | | | |!| | |!| | | | | |!| | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | |!| | |`|-| D01 |-|(| | | | |D01=Anti-factor Xa therapy }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | |!| | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | |`| B01 | |B01=[[Fondaparinux]] }}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
| |
| {{familytree | | | | | | | | | | | | P01 | | | | | | | | | | | | | | | | | | | | | | | | | | |P01=Proceed to serologic testing}}
| |
| {{familytree | | | | | | | | | | | | |!| | | | | | | | }}
| |
| {{familytree | | | | | | |,|-|-|-|v|-|^|-|-|v|-|-|-|.| | | | | | }}
| |
| {{familytree | | | | | | |!| | | |!| | | | |!| | | |!| | | | }}
| |
| {{familytree | | | | | | Q01 | | Q02 | | | Q03 | | Q04 | | | | | | | | | | | | | | | | | | | | |Q01=Positive + high clinical suspicion of HIT |Q02=Positive + intermediate suspicion of HIT |Q03=Negative + high clinical suspicion of HIT |Q04=Negative + intermediate clinical suspicion of HIT }}
| |
| {{familytree | | | | | | |!| | | |!| | | | |!| | | |!| | | | | | | | | | | | | | | | | | |}}
| |
| {{familytree | | | | | | R01 | | R02 | | | R03 | | R04 | | | | | | | | | | | | | | | | | | | | |R01=Confirmed HIT |R02=Proceed to functional testing |R03=Indeterminate HIT |R04=Can restart heparin }}
| |
| {{familytree | | | | | | | | | | |!| | | | |!| | | |!| ||}}
| |
| {{familytree | | | | | | |,|-|-|-|^|-|-|.| |!| | | |!| | }}
| |
| {{familytree | | | | | | |!| | | | | | |!| |!| | | |!| | | | }}
| |
| {{familytree | | | | | | Q01 | | | | | Q02 |!| | | |!| | | | | | | | | | | | | | | | |Q01=C-Serotonin Release Assay (SRA) |Q02=Heparin induced platelet-activation assays (HIPA) }}
| |
| {{familytree | | | | | | | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | | | | | | |}}
| |
| {{familytree | | | | | | | | | | | | | | | S01 | | S02 | | | | | | | | | | | | | | | | | | | | |S01=Rule out other causes of thrombocytopenia |S02=Rule out other causes of thrombocytopenia }}
| |
| {{familytree/end}}
| |
|
| |
|
| ==References== | | ==References== |
| {{Reflist|2}} | | {{Reflist|2}} |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernandez, M.D. [2]
Definition
Heparin induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that predisposes to elevated risks of arterial and venous thromboembolism.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Screening for HIT
| | ❑ Asses the risk of HIT | | |
| | | | | | | |
| |
Patient Population (Minimum of 4-d Exposure) | Incidence of HIT, % |
Postoperative patients | |
Heparin, prophylactic dose | 1-5 |
Heparin, therapeutic dose | 1-5 |
Heparin, flushes | 0.1-1 |
LMWH, prophylactic or therapeutic dose | 0.1-1 |
Cardiac surgery patients | 1-3 |
Medical patients | |
Patients with cancer | 1 |
Heparin, prophylactic or therapeutic dose | 0.1-1 |
LMWH, prophylactic or therapeutic dose | 0.6 |
Intensive care patients | 0.4 |
Heparin, flushes | < 0.1 |
Obstetrics patients | <0.1 |
| |
| | | | | | | | | | |
| | | | | |
Risk <1% | | Risk >1% |
| | | | | | | | | |
❑ Do not monitor platelet count | | ❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) |
Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]
Diagnostic Approach to HIT
| | | Thrombocytopenia ❑ Platelet count <150,000/mm 3, OR ❑ >30-50% decrease decrease of platelet from baseline
❑ Recent heparin or LMWH use in the previous 5- 14 days | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | Characterize the symptoms (if present): ❑ Arterial thromboembolism ❑ Venous thromboembolism ❑ Unusual manifestations:
- Skin necrosis at SC heparin injection sites
- Transient global amnesia
❑ Absence of petechiae and/or significant bleeding | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | Suspicion of HIT | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | |
Low clinical probability | | | | Intermediate/high clinical probability | | | | | | |
| | | | | | | | | | | | | | | | | |
Unlikely HIT ❑ Consider alternative diagnoses ❑ Continue heparin | | | | ❑ Discontinue heparin ❑ Begin alternative anticoagulation | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | ❑ Order anti PF4 antibodies | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
Moderately/strongly positive test | | Weakly positive test Plus High clinical probability | | Weakly positive test PLUS Intermediatre clinical probability | | Negative |
| | | | | | | | | | | | | | | | | | | |
| | ❑ Order functional assay | | | | | | Unlikely HIT ❑ Consider alternative diagnoses ❑ Continue heparin | | |
| | | | | | | | | | | | | | | | | | |
| | | | | |
Positive test Likely HIT | | Negative test HIT undetermined | | | | | | | | |
The most studied functional assays are serotonin release assay (SRA) and Heparin induced platelet activation assay (HIPA).[2]
The diagnostic algorithm is based on "How I treat heparin-induced thrombocytopenia" from Blood (2012).[2]
Special Considerations
Shown below is a table summarizing the appropriate choice of anticoagulation therapy in special situations.[1]
References